Arcus Biosciences Q2 revenue falls sharply on lower license income

Arcus Biosciences

05/08/2026 21:47

Overview
U.S. biopharma firm's Q2 revenue fell sharply yr/yr due to prior one-time license revenue
Company posted Q2 net loss as R&D expenses outpaced revenue
Arcus ended Q2 with $775 mln in cash, expects runway into 2028

Outlook
Arcus expects 2026 GAAP revenue between $65 mln and $75 mln
Company expects to end 2026 with about $600 mln in cash
Arcus anticipates cash runway until at least the second half of 2028

Result Drivers
REVENUE DECLINE DRIVERS - Co said Q2 revenue drop was mainly due to prior-year one-time license and development services revenue, partially offset by new access rights and collaboration income
R&D EXPENSES DOWN - R&D costs fell due to winding down late-stage and early-stage programs, offset by increased investment in casdatifan and immunology pipeline
COST SAVINGS - G&A expenses declined due to streamlining initiatives across operations

Company press release: ID:nBw7NzWQWa

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Net Loss
 
$91 mln
 
Q2 Operating Expenses
 
$137 mln
 
Q2 Operating Income
 
-$96 mln
 
Q2 Pretax Loss
 
$91 mln
 

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 10 "strong buy" or "buy", 3 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Arcus Biosciences, Inc. is $38.00, about 31.9% above its August 4 closing price of $28.80

Reuters Recommended Reads
Aug 5 - EyePoint Pharmaceuticals Q2 revenue drops on lower license income
Aug 5 - Immuneering expects cash runway to fund operations into 2029
Aug 4 - Dianthus Therapeutics Q2 net loss widens as R&D costs rise

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)